Toggle

Toggle Therapeutics is a biotechnology company pioneering the development of "switchable" aptamer-based therapeutics. The company's proprietary platform enables the creation of drugs whose activity can be precisely controlled—turned on or off—using small molecule "toggles," which aims to enhance safety and efficacy profiles. Currently, Toggle is focusing its efforts on metabolic disorders, specifically targeting the GLP-1 receptor for obesity and diabetes, as well as developing reversible anticoagulants for hematological applications. The approach combines the high affinity and specificity of biologics with the controllable pharmacokinetics typically associated with smaller molecules.